Bortezomib-induced pneumonitis during bortezomib retreatment in multiple myeloma

Japanese Journal of Clinical Oncology

Volumn 42, Issue 7, 2012, Pages 637-639

  Yamaguchi, Takeshi ^a   Sasaki, Masaoki ^a   Itoh, Kuniaki ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Complications; Dyspnea; Lung injury; Pneumonia; Steroids

Indexed keywords

ALBUMIN; BORTEZOMIB; CALCIUM; DEXAMETHASONE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LAMBDA CHAIN; MELPHALAN; OXYGEN; PREDNISOLONE; SULTAMICILLIN; ZOLEDRONIC ACID;

ABNORMAL RESPIRATORY SOUND; ADULT; AMBIENT AIR; ANEMIA; ANOREXIA; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BONE LESION; BONE MARROW; BORTEZOMIB INDUCED PNEUMONITIS; CANCER RELAPSE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE SEVERITY; DRUG MEGADOSE; DYSPNEA; FEVER; GAMMOPATHY; HUMAN; HYDRATION; HYPERCALCEMIA; HYPERLIPOPROTEINEMIA; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; JAPANESE; KIDNEY DYSFUNCTION; LOW BACK PAIN; LOW DRUG DOSE; LUNG INFILTRATE; LUNG LOBE; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OXYGEN SATURATION; OXYGEN THERAPY; PANCYTOPENIA; PHYSICAL EXAMINATION; PLASMA CELL; PNEUMONIA; RETREATMENT; STEROID THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PNEUMONIA; PYRAZINES; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84864374523     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys074     Document Type: Article

References (11)

1. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
2. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
3. Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010;28:4621-9.
4. Boyer JE, Batra RB, Ascensao JL, et al. Severe pulmonary complication after bortezomib treatment for multiple myeloma. Blood 2006;108:1113.
5. Chew E, Filshie R, Wei A. Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone. Leuk Lymphoma 2007;48:212-3.
6. Pitini V, Arrigo C, Altavilla G, et al. Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis? Leuk Res 2007;31:1027-8.
7. Zappasodi P, Dore R, Castagnola C, et al. Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma. J Clin Oncol 2007;25:3380-1.
8. Dun X, Yuan Z, Fu W, et al. Severe pulmonary complications after bortezomib treatment in multiple myeloma. Hematol Oncol 2010;28:49-52.
9. Zhou X, Sun C, Wang J, et al. Rapid fatal pulmonary complications in a Chinese patient after bortezomib treatment for ALK-negative anaplastic large-cell lymphoma. Clin Lymphoma Myeloma Leuk 2010;10:152-4.
10. Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011;117:4691-5.
11. Miyakoshi S, Kami M, Yuji K, et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 2006;107:3492-4.